Praveen K. Tumula

An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Lauren A. Byers, Lixia Diao, Jing Wang et al. · Clinical Cancer Research · 2012 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +17

Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren A. Byers, Jing Wang, Monique B. Nilsson et al. · Cancer Discovery · 2012 · 571 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study

Mazyar Shadman, Ian W. Flinn, Moshe Levy et al. · The Lancet Haematology · 2022 · 89 citations

Medicine, Oncology, Pharmacology +14

Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients (Pts) with Relapsed/Refractory B-Cell Malignancies

Mazyar Shadman, Ian W. Flinn, Moshe Levy et al. · Blood · 2021 · 24 citations

Medicine, Pharmacology, Pharmacotherapy +9